TerminatedNCT00917293
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Medication studyAges 18–65Canada + IndiaSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Victoria and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMay 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 53
- Sponsor
- Medicure
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada, India
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00917293
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Victoria, Canada · Toronto, Canada · Windsor, Canada
1 more locations
- Chennai, India
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medicure.
Does this study involve medication?
Yes. The study involves medication, including Pyridoxal 5'-Phosphate and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
